कंपनी का अवलोकन
Vanda Pharmaceuticals Inc. operates as a biopharmaceutical entity dedicated to the research, development, and commercialization of therapeutic interventions designed to address significant unmet medical needs globally. The company functions within the healthcare sector, specifically targeting the biotechnology industry, where innovation in drug discovery and clinical trial execution defines its operational scope. As of the latest reporting period, the enterprise holds a market capitalization of $430.90M and generates an annual revenue of $216.10M while employing a workforce of 533 individuals. These financial figures indicate that Vanda maintains a mid-cap status, suggesting a company that has moved beyond early-stage development but has not yet achieved the massive scale of a large-cap pharmaceutical giant, placing it in a phase where capital efficiency is critical for sustaining operations and funding further R&D initiatives.
वित्तीय स्वास्थ्य
The company reported a total revenue of $216.10M over the trailing twelve months, yet recorded a net income of -$220,474,000, highlighting a substantial gap that reveals a heavy cost structure where expenses significantly exceed gross revenue generation. This disparity is further evidenced by an EBITDA figure of -$143,058,000, indicating that core operating activities are not yet generating positive cash conversion before financing and non-operating costs. Free cash flow stands at -$49,359,000, which signifies that the company is currently consuming cash reserves to fund its business model rather than returning capital to stakeholders or acquiring other assets. The gross margin is recorded at 94.0%, reflecting the high value-added nature of biopharmaceutical products before accounting for operational overheads, while the operating margin of -70.5% and profit margin of -102.0% demonstrate that substantial operational and selling, general, and administrative costs are eroding profitability. On the balance sheet, the company holds $263.85M in cash against $12.62M in debt, resulting in a debt-to-equity ratio of 3.86, which suggests a leveraged position reliant on equity financing rather than debt servicing given the negative earnings. The current ratio of 2.39 indicates robust short-term liquidity, as current assets are more than twice the value of current liabilities, providing a comfortable buffer against immediate obligations. Return on equity is -50.9% and return on assets is -16.5%, metrics that reveal that management is currently unable to generate positive returns on the capital invested, a common characteristic for biotechnology firms in high-investment clinical phases.
मूल्यांकन आकलन
Valuation metrics for Vanda show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at 36.45, implying that the market prices the stock based on anticipated future profitability rather than historical performance. The price-to-book ratio is 1.32, indicating that the market values the company's equity at a 32% premium over its book value, likely reflecting intangible assets such as intellectual property and pipeline potential that are not captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 1.99 and an EV/EBITDA of -1.26, suggesting that the stock is priced relative to revenue generation rather than earnings power, a standard practice for pre-profitability biotech firms. The 52-week trading range spans from a low of $3.81 to a high of $9.94, meaning the current market price fluctuates within this established band, though the exact current price relative to the high is not specified in the provided data points. The beta value of 0.71 suggests that the stock exhibits lower volatility compared to the broader market, moving less sharply in response to general market swings, which may appeal to investors seeking relative stability within the volatile biotechnology sector.
Growth & Income
Revenue growth year-over-year is recorded at 7.6%, while earnings growth is N/A due to the company's negative net income position. The absence of positive earnings growth relative to revenue growth implies that the company is prioritizing expansion and market penetration over immediate profitability, a strategic choice typical for firms developing novel therapies. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders, indicating that all available cash is retained to fund research, development, and commercialization efforts. Consequently, the overall growth and income profile is defined by organic revenue expansion and the strategic reinvestment of capital to advance the commercial portfolio, including products like Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder, rather than income generation through dividends or buybacks.